Get the Stockscreener App
813.53
0.80%
-6.57
After Hours:
808.80
-4.73
-0.58%
Overview
News
Price History
Option Chain
Financials
Why LLY Down?
Discussions
Forecast
Stock Split
Dividend History
Lilly Eli Co stock is traded at $813.53, with a volume of 3.54M.
It is down -0.80% in the last 24 hours and up +11.98% over the past month.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
See More
Previous Close:
$820.10
Open:
$827.31
24h Volume:
3.54M
Relative Volume:
0.79
Market Cap:
$769.97B
Revenue:
$53.26B
Net Income/Loss:
$13.80B
P/E Ratio:
53.94
EPS:
15.0808
Net Cash Flow:
$-50.20M
1W Performance:
+0.14%
1M Performance:
+11.98%
6M Performance:
-8.10%
1Y Performance:
-9.97%
1-Day Range:
$809.63
$830.29
1-Week Range:
$806.02
$834.15
52-Week Range:
$623.78
$935.62
Lilly Eli Co Stock (LLY) Company Profile
Name
Lilly Eli Co
Sector
Industry
Phone
(317) 276-2000
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
813.53 | 735.18B | 53.26B | 13.80B | -50.20M | 15.08 |
|
JNJ
Johnson Johnson
|
186.60 | 450.37B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
225.14 | 401.96B | 58.33B | 3.73B | 18.24B | 2.1013 |
|
NVS
Novartis Ag Adr
|
121.80 | 238.94B | 53.40B | 13.68B | 16.89B | 6.8864 |
|
MRK
Merck Co Inc
|
86.58 | 217.38B | 63.43B | 16.42B | 14.72B | 6.4861 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-20-25 | Reiterated | BMO Capital Markets | Outperform |
| Oct-14-25 | Upgrade | Erste Group | Hold → Buy |
| Sep-17-25 | Downgrade | Berenberg | Buy → Hold |
| Aug-27-25 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-18-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Aug-07-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-05-25 | Downgrade | Erste Group | Buy → Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Reduce |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Sep-13-24 | Resumed | Citigroup | Buy |
| Aug-12-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-21-24 | Downgrade | DZ Bank | Buy → Hold |
| Feb-16-24 | Reiterated | Morgan Stanley | Overweight |
| Dec-21-23 | Downgrade | Daiwa Securities | Buy → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-20-23 | Resumed | UBS | Buy |
| Aug-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-26-23 | Reiterated | Citigroup | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-24-23 | Reiterated | BofA Securities | Buy |
| May-24-23 | Reiterated | UBS | Buy |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-15-23 | Downgrade | Societe Generale | Hold → Sell |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Sep-22-22 | Upgrade | UBS | Neutral → Buy |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Mar-10-22 | Initiated | Daiwa Securities | Outperform |
| Jan-21-22 | Upgrade | DZ Bank | Hold → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-16-21 | Reiterated | BMO Capital Markets | Outperform |
| Dec-16-21 | Reiterated | BofA Securities | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-11-21 | Upgrade | Berenberg | Hold → Buy |
| Sep-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-05-21 | Upgrade | DZ Bank | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Jun-24-21 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-19-21 | Upgrade | Mizuho | Neutral → Buy |
| Dec-10-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Sep-03-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-21-20 | Downgrade | UBS | Buy → Neutral |
| Apr-09-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-18-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-28-19 | Initiated | Goldman | Buy |
| Apr-24-19 | Upgrade | Edward Jones | Hold → Buy |
| Apr-11-19 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-19 | Initiated | JP Morgan | Overweight |
| Jan-23-19 | Initiated | UBS | Buy |
| Nov-26-18 | Downgrade | Citigroup | Buy → Neutral |
| Oct-31-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Oct-01-18 | Reiterated | SunTrust | Buy |
| Sep-26-18 | Resumed | JP Morgan | Overweight |
View All
Lilly Eli Co Stock (LLY) Latest News
Forex Signals Oct 30: BoJ, ECB Steady, Trump Meets Xi; Apple, Amazon, and Eli Lilly Q3 - FXLeaders
Eli Lilly partners with Walmart to sell weight-loss drug directly to patients nationwide - Fox Business
Eli Lilly Reports Earnings Thursday as Investors Await Trump Drug Pricing Deal - Barron's
Lilly Takes Big Step Forward In AI With NVIDIA Partnership - Citeline News & Insights
Eli Lilly (LLY) Anticipates Strong Q3 Earnings Surge - GuruFocus
Eli Lilly Partners With Walmart To Expand Access To Popular Weight-loss Drug - Stocktwits
Eli Lilly to Invest $1.2 Billion in Puerto Rico Manufacturing Expansion - Yahoo! Finance Canada
Eli Lilly (LLY) Invests $1.2 Billion in Puerto Rico Manufacturing Plant - TipRanks
Lilly Forms Partnership with NVIDIA to Create AI Supercomputer - Pharmaceutical Executive
Eli Lilly Advances AI And Access: Supercomputer With NVIDIA, Zepbound Via Walmart - Benzinga
Eli Lilly, Walmart to offer first retail pickup option for discounted vials of weight loss drug Zepbound - CNBC
Eli Lilly Pours $1.2 Billion Into Puerto Rico Expansion - Finimize
Eli Lilly, Walmart launch retail pick-up option for weight loss drug Zepbound - Fierce Healthcare
Eli Lilly’s New Study on Baricitinib: A Potential Game-Changer for Type 1 Diabetes - TipRanks
NVIDIA hits $5T valuation, teams up with Lilly to build AI supercomputer - Mobi Health News
Lilly plans $1.2B expansion in Puerto Rico, adding 100 manufacturing jobs - Inside INdiana Business
Eli Lilly Commits Over $1.2 Billion to Expand Puerto Rico Manufacturing Hub - BioSpectrum Asia
Eli Lilly to invest $1.2 billion in Puerto Rico as part of US manufacturing push - WTVB
Eli Lilly to invest historic $1.2 Billion in expansion - The Weekly Journal
Eli Lilly, Walmart Announce Expansion of Direct-to Consumer Access for Tirzepatide - Drug Topics
Jim Cramer on Eli Lilly Stock “Needs Some Kind of Catalyst to Get Things Going” - Yahoo! Finance UK
Lilly aligns with Walmart in bid to broaden access to discounted Zepbound - BioPharma Dive
Lilly, Walmart launch discount retail option for weight-loss drug Zepbound - Reuters
Eli Lilly, Walmart partner to bring Zepbound to customers with direct-to-consumer pricing - KIRO 7 News Seattle
Walmart, Eli Lilly partner to expand direct-to-consumer Zepbound pricing - Mass Market Retailers
Eli Lilly to Invest $1.2 Billion in Puerto Rico Plant Expansion - MarketScreener
Eli Lilly (LLY) Pours $1.2 Billion into Puerto Rico Expansion - GuruFocus
Eli Lilly to invest $1.2B in Puerto Rico plant - breakingthenews.net
Walmart and Eli Lilly to Offer In-Store Pickup for Zepbound With Direct-to-Consumer Pricing - PYMNTS.com
Lilly expands Zepbound direct-to-patient access through Walmart partnership - Indianapolis Business Journal
Lilly Announces Partnership with Walmart Pharmacy Launching First Retail Pick-Up Option Offering Direct-To-Consumer Priced Zepbound - Pharmaceutical Commerce
Eli Lilly announces over $1.2B investment in Puerto Rico faciliy - TipRanks
Eli Lilly invests $1.2 billion to expand Puerto Rico manufacturing site - StreetInsider
Lilly announces more than $1.2 billion investment in Puerto Rico facility to boost oral medicine manufacturing capacity in the United States - MarketScreener
In Lilly vs Novo obesity drug battle, Trump price talks grab focus - MarketScreener
What's the Driving Force Behind Eli Lilly's Recent Acquisition Spree? - The Globe and Mail
Eli Lilly (LLY) and Walmart Partner to Expand Access to Zepbound - GuruFocus
Eli Lilly, Walmart bring retail pick-up option with DTC pricing for Zepbound (WMT:NYSE) - Seeking Alpha
Eli Lilly strikes deal with Walmart to distribute cash-pay Zepbound vials - Sherwood News
Lilly, Walmart launch first retail pick-up option for weight-loss drug - Yahoo! Finance Canada
Lilly, Walmart Launch Discount Retail Option for Weight-Loss Drug Zepbound - US News Money
Eli Lilly Taps Nvidia to Build Pharma’s Most Powerful AI Supercomputer for Drug Discovery - WinBuzzer
Eli Lilly acquires Adverum to advance one-time gene therapy for vision loss - BioXconomy
Why Eli Lilly and Company stock is a strong buy callJuly 2025 Spike Watch & Accurate Trade Setup Notifications - Fundação Cultural do Pará
Top News Today: Lilly-NVIDIA AI Drug Discovery Deal, Sequoia’s $950M Fund Launch - Analytics Insight
Eli Lilly and Nvidia team up to build an AI supercomputer dedicated to drug discovery - MarketScreener
Eli Lilly partners with Nvidia to build AI supercomputer for drug discovery | Mint - Mint
Opportunities Amid Stock Price Correction? Decoding Eli Lilly’s Moat and Growth Potential - NAI500
Lilly partners with Nvidia on AI supercomputer to speed up drug development - The Hindu
Eli Lilly (LLY) To Report Earnings Tomorrow: Here Is What To Expect - Yahoo Finance
Lilly, Nvidia team up to build pharma’s ‘most powerful’ supercomputer - Indianapolis Business Journal
Lilly Eli Co Stock (LLY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.18%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):